The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of azacitidine (AZA) plus pembrolizumab (pembro) as second-line treatment in patients with advanced pancreatic ductal adenocarcinoma.
 
Rachael A Safyan
Research Funding - Merck (Inst)
 
Gulam Abbas Manji
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - Celgene; Exelixis; Roche/Genentech
Consulting or Advisory Role - BiolineRx; CEND Pharmaceuticals; Exelixis; Ipsen; Roche/Genentech
Research Funding - BiolineRx (Inst); Merck (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; Exelixis; Roche/Genentech
 
Shing Mirn Lee
Consulting or Advisory Role - PTC Therapeutics
Research Funding - Merck (Inst)
 
Rebecca Silva
No Relationships to Disclose
 
Susan Elaine Bates
Honoraria - Merck (I)
Consulting or Advisory Role - Akita Biomedical (I); ElmediX; OnKure; Pegascy; Secura Bio (I); SERVIER
Research Funding - Amgen (Inst); Ipsen (Inst); Merck (Inst); Pfizer; Pfizer (Inst); RenovoRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent: Deacetylase Inhibitor Therapy (Inst); Patent: Depsipeptide for Therapy of Kidney Cancer (Inst)
 
Ruth Aroon White
No Relationships to Disclose
 
Jacob K.R. Jamison
No Relationships to Disclose
 
Adam Joel Bass
Leadership - Earli; Helix Nanotechnologies; Signet Therapeutics
Stock and Other Ownership Interests - Earli; Helix Nanotechnologies; Signet Therapeutics
Consulting or Advisory Role - Roche; Silverback Therapeutics
Research Funding - Bayer; Novartis; Repare Therapeutics
Travel, Accommodations, Expenses - Lilly
 
Gary K. Schwartz
Stock and Other Ownership Interests - Bionaut Labs; GenCirq; January Therapeutics
Consulting or Advisory Role - Apexigen; Array BioPharma; Astex Pharmaceuticals; Bionaut Labs; Concarlo; Ellipses Pharma; Epizyme; Gencirq; January Therapeutics; Oncogenuity; OnCusp Therapeutics; PureTech; Sellas Life Sciences; Shanghai Pharma
Research Funding - Adaptimmune (Inst); Astex Pharmaceuticals; Astex Pharmaceuticals (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Oxford BioTherapeutics (Inst); SpringWorks Therapeutics (Inst); TopAlliance BioSciences Inc (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Epizyme; Epizyme; Epizyme
 
Paul Eliezer Oberstein
Consulting or Advisory Role - AstraZeneca; Delcath Systems; Merck; QED Therapeutics; Rubius Therapeutics
Speakers' Bureau - AstraZeneca
Research Funding - Arcus Biosciences (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Roche/Genentech (Inst)
Expert Testimony - Ipsen
Travel, Accommodations, Expenses - Merck
 
Tamas Gonda
Honoraria - Boston Scientific; Cook Medical
Consulting or Advisory Role - Taewoong Endoscopy
Speakers' Bureau - Cook Medical
Research Funding - Boston Scientific; Merck